Monomethyl Auristatin F is a pharmaceutical ingredient whose molecular pharmacology encompasses primary target interactions, off-target binding to safety-relevant proteins, and concentration-response relationships that collectively determine whether pharmacologically-based or NOAEL-based OEL derivation methodology is more protective for occupationally exposed workers. The identification of the critical pharmacodynamic effect and its dose-response threshold in humans—from clinical pharmacology studies or clinical pharmacokinetic-pharmacodynamic modelling—provides a scientifically superior basis for OEL derivation compared to default interspecies extrapolation from animal toxicity data.
Reproductive and developmental toxicity findings for Monomethyl Auristatin F receive an additional severity factor consideration in PDE derivation, because pharmaceutical patient populations frequently include women of childbearing potential and, in some indications, pregnant patients.
